Stipple Bio

Excited to be featured in @BioCentury, highlighting our epitope-level approach to identifying tumor-specific targets and enabling more selective #cancer therapies. Read more: bit.ly/4sBEiTp

Following our recent Series A news, we’re excited to be featured on the Nasdaq Tower in Times Square. Thank you to @Nasdaq for the spotlight. #PrecisionOncology

We will take all space rocket imagery in biotech land … especially when we’re working on drugging novel tumor-specific epitopes to treat really difficult cancers A big congrats on the company launch and $100m series A financing to @a16z portfolio company @stipplebio! fiercebiotech.com/biotech/buoyed…

Come for the bold #cancer #biotech fundraise headline, stay for the beautiful mountain climbing analogy from @stipplebio co-founder @aaronmring Thank you @ldtimmerman for the spot-on coverage describing “epitomics” and why we are betting that it will yield novel handles (and binders) for tumor-specific biology

Proud to be featured by @a16z on why they’re investing in Stipple Bio as they share their perspective on the opportunity to unlock new targets in oncology through epitope-level precision. open.substack.com/pub/a16z/p/inv…

Today, we announced $100 million oversubscribed Series A financing to support advancement of our lead candidate, STP-100, and Pointillist Platform, designed to identify tumor-specific cell surface epitopes, enabling development of #precisiononcology medicines. bit.ly/3Q5BakV